 SOUTH SAN FRANCISCO, Calif., Sept. 17, 2021 PRNewswire -- Sutro Biopharma, Inc. NASDAQ: STRO, a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that on September 15, 2021, the Compensation Committee of Sutros Board of Directors granted restricted stock unit awards RSUs representing an aggregate of 150,000 shares of Sutro common stock and stock options to purchase an aggregate of 145,000 shares of Sutro common stock to 3 new employees. 